Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | AVPR1A | P37288 | 14/20 | 0.55 |
| ▸ | AVPR2 | P30518 | 10/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307924 | 0.86 | LMNA (0.54) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL1308282 | 0.83 | LMNA (0.61) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL3455435 | 0.81 | LMNA (0.56) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL3455465 | 0.79 | ALDH1A1 (0.74) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL3454816 | 0.79 | LMNA (0.63) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL3454755 | 0.79 | AVPR1A (0.61) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL3455659 | 0.79 | LMNA (0.60) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL12576936 | 0.79 | AVPR1A (0.74) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL3455832 | 0.78 | HSD11B1 (0.56) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL3456861 | 0.78 | AVPR1A (0.62) | LMNAALDH1A1MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | claimed |
| EP-1945207-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | Transtech Pharma, Inc. (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2007051811-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | claimed |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
| EP-1945207-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | Transtech Pharma, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007051811-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007051811-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, CYP11B1, HSD11B2 | LMNA 3649/4885ALDH1A1 187/4885MEN1 1971/4885 |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | LMNA 3468/4885ALDH1A1 206/4885MEN1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.